Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
暂无分享,去创建一个
R. Gelber | B. Gusterson | A. Goldhirsch | G. Viale | M. Regan | A. Coates | D. Crivellari | K. Price | M. Castiglione‐Gertsch | J. Lindtner | S. Aebi | R. Gelber | A. Coates | P. Karlsson | Zhuoxin Sun | R. Snyder | E. Simoncini | M. Rabaglio | D. Braun | G. Viale | M. Regan | Z. Sun | Danielle Braun
[1] M. Bonetti,et al. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Gelber,et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Thigpen. Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen , 2010 .
[4] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[5] C. Sotiriou,et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] F. Penault-Llorca,et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Loibl,et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.
[8] R. Gelber,et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. V. van't Veer,et al. Clinical application of the 70-gene profile: the MINDACT trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Paik,et al. Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Gelber,et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.
[12] M. Dowsett,et al. International Web-based consultation on priorities for translational breast cancer research , 2007, Breast Cancer Research.
[13] R. Arriagada,et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Gelber,et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. , 2006, Journal of the National Cancer Institute.
[16] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Norman Wolmark,et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Bryant,et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials , 2004, The Lancet.
[19] M. Bonetti,et al. Patterns of treatment effects in subsets of patients in clinical trials. , 2004, Biostatistics.
[20] M. J. van de Vijver,et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.
[21] M. Bonetti,et al. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. , 2002, Journal of the National Cancer Institute.
[22] M. Bonetti,et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF , 2002, British Journal of Cancer.
[23] M. Bonetti,et al. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. , 2000, Statistics in medicine.
[24] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .